StockWatch
·

ALEMBIC LTD. Q2 FY27 Results

ALEMBICLTDQ2 FY27 Results
Filing
Result:Weak· Market: Down#One-off gain#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue30.2538.0%45.9%
Total Income101.8086.1%15.7%
Expenditure29.0422.3%19.3%
PBT72.76319.6%14.2%
Net Profit162.87151.0%26.8%
OPM17.47%14.24pp24.13pp
NPM100.00%0.00pp0.00pp
EPS6.34150.6%26.8%
View full financials

Core Real Estate segment revenue (77% of sales) fell 48.5% YoY with segment profit down 77%, and adjusted PAT (ex-Pharma equity share) fell 11.2% YoY, so the headline 26.8% PAT beat is entirely non-operating (associate income + fair-value gain), not a genuine operating improvement.

Q2 FY-2027 RESULTS · ALEMBICLTD

Alembic consol PAT +27% YoY to ₹163 Cr on stake gains; core profit -11%, revenue -46%

PAT +26.76% YoY · revenue -45.86% · margins compressing

06 Nov 2026 · 3 min read
Revenue

₹30.25 Cr

-45.86% YoY

PAT (consolidated)

₹162.87 Cr

+26.76% YoY

Net margin

159.99%

+60pp YoY

EPS

₹6.34

Alembic Ltd's consolidated PAT for Q2 FY27 came in at ₹162.87 Cr, up 26.8% YoY from ₹128.49 Cr and up 151.0% QoQ from ₹64.89 Cr (Q1 FY27 was a seasonal trough). Revenue from operations, however, fell 45.9% YoY and 37.9% QoQ to ₹30.25 Cr, and operating margin (segment EBIT/revenue) compressed to roughly 14.9% from ~40% a year ago and ~32% last quarter. On a core basis — PAT before the equity-method share of Alembic Pharmaceuticals' earnings — profit was ₹67.57 Cr, DOWN 11.2% YoY from ₹76.06 Cr; the entire headline PAT gain is non-operating, so the adjusted (core) YoY read is a decline, not growth.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹30.25 Cr-37.9%-45.8%
Expenses₹29.04 Cr-22.3%-19.3%
PAT₹162.87 Cr+151%+26.76%
Net margin159.99%+60pp+60pp
EPS₹6.34+150.6%+26.8%

The bridge sits in two lines outside the operating P&L: a ₹95.30 Cr share of Associate's profit (Alembic Pharmaceuticals, equity-method consolidated) and a ₹68.28 Cr unallocable dividend/fair-value-gain item, together ₹163.58 Cr against total segment income of just ₹101.80 Cr. Within operations, Real Estate — 77% of consolidated revenue at ₹23.45 Cr — fell 48.5% YoY and 36.7% QoQ on project/possession-timing lumpiness, with segment profit down 77% YoY to ₹4.67 Cr. The API business (₹6.79 Cr revenue, -34% YoY) swung to a small segment operating loss of ₹(0.17) Cr from a ₹1.95 Cr profit a year ago.

₹
80.0388.7197.4106.09114.77101.2208-0308-2509-1710-1211-0411-06Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹101.22, down 2.3% over the past month of trading.

₹ Cr
060.8121.61182.4161.64Q1 FY26rev ₹50 Cr128.49Q2 FY26rev ₹56 Cr60.13Q3 FY26rev ₹74 Cr67.13Q4 FY26rev ₹60 Cr64.89Q1 FY27rev ₹49 Cr162.87Q2 FY27rev ₹30 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records.

Alembic Ltd (the holding company, distinct from the separately listed Alembic Pharmaceuticals) has no tracked street consensus and no management guidance on record; a web search for Q2 FY27 previews found no verified analyst estimates, consistent with thin coverage of this stock — vsStreet and vsGuidance are both unknown, and no management press release was available to cross-check framing. The pattern echoes our record of Q1 FY27 (PAT +5% YoY to ₹65 Cr, 'propped up by Pharma stake; core profit -12%') — a second straight quarter where consolidated PAT growth comes from the Pharma stake rather than the Real Estate and API operating businesses. Standalone PAT of ₹67.02 Cr (EPS ₹2.61) is less than half the consolidated ₹162.87 Cr (EPS ₹6.34), confirming the gap sits entirely in the associate-method consolidation adjustment. H1 FY27 consolidated PAT of ₹227.74 Cr is up 19.8% YoY (₹190.13 Cr), still carried by the same non-operating items.

  • W1

    Real Estate segment revenue recovery — H1 FY27 segment revenue ₹60.48 Cr is down 26.6% YoY (₹82.35 Cr); watch for project possessions to resume in H2

  • W2

    API segment profitability — whether the Q2 operating loss of ₹(0.17) Cr reverses or persists next quarter

  • W3

    Associate-income cadence from Alembic Pharmaceuticals (₹95.30 Cr this quarter) — the swing factor behind headline consolidated PAT each quarter

Informational and educational content only. Not investment advice.